{"protocolSection": {"identificationModule": {"nctId": "NCT01080768", "orgStudyIdInfo": {"id": "CSPA100A2201"}, "secondaryIdInfos": [{"id": "2009-014359-63", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension", "officialTitle": "A Double Blind, Randomized, Parallel Study to Assess the Effects of Aliskiren/Amlodipine and Amlodipine Monotherapy on Ankle Foot Volume (AFV) in Patients na\u00efve to Trial Drugs With Mild to Moderate Hypertension"}, "statusModule": {"statusVerifiedDate": "2011-11", "overallStatus": "TERMINATED", "whyStopped": "Publication of data from a similar study made the current study redundant.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-02"}, "primaryCompletionDateStruct": {"date": "2010-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-03-03", "studyFirstSubmitQcDate": "2010-03-03", "studyFirstPostDateStruct": {"date": "2010-03-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-11-22", "resultsFirstSubmitQcDate": "2011-11-22", "resultsFirstPostDateStruct": {"date": "2011-12-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-11-22", "lastUpdatePostDateStruct": {"date": "2011-12-26", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of the present study was to evaluate the addition of aliskiren, to amlodipine can attenuate ankle edema formation in hypertensive patients."}, "conditionsModule": {"conditions": ["Hypertension", "Ankle Edema"], "keywords": ["Pedal edema", "hypertension", "aliskiren", "amlodipine"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 31, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aliskiren/amlodipine + Placebo to amlodipine", "type": "EXPERIMENTAL", "description": "During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.\n\nThe patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day.", "interventionNames": ["Drug: Aliskiren/amlodipine", "Drug: Placebo to Amlodipine"]}, {"label": "Amlodipine + Placebo to aliskiren/amlodipine", "type": "ACTIVE_COMPARATOR", "description": "During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.\n\nThe patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day.", "interventionNames": ["Drug: Amlodipine", "Drug: Placebo to Aliskiren/amlodipine"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren/amlodipine", "description": "Aliskiren/amlodipine 150/5 mg/day", "armGroupLabels": ["Aliskiren/amlodipine + Placebo to amlodipine"], "otherNames": ["SPA100"]}, {"type": "DRUG", "name": "Amlodipine", "description": "Amlodipine 5 mg/day.", "armGroupLabels": ["Amlodipine + Placebo to aliskiren/amlodipine"]}, {"type": "DRUG", "name": "Placebo to Aliskiren/amlodipine", "description": "Placebo to Aliskiren/amlodipine 150/10 mg/day", "armGroupLabels": ["Amlodipine + Placebo to aliskiren/amlodipine"]}, {"type": "DRUG", "name": "Placebo to Amlodipine", "description": "Placebo to Amlodipine 5 mg/day", "armGroupLabels": ["Aliskiren/amlodipine + Placebo to amlodipine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in the Ankle Foot Volume (AFV) as Measured by Displacement Method", "description": "AFV (mL) was measured using the principle of water displacement using a commercially available foot volumeter. The amount of water displaced in milliliters (mL) equals the volume of the foot/ankle. The study was terminated due to the publication of the results of a near identical study by Fogari et al. Hence, for the current study, no analysis was performed.", "timeFrame": "Baseline, 4 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients (male or female) with hypertension aged between 18-75 yrs.\n* Patients not treated with amlodipine or no amlodipine in previous 1 year.\n* Post-menopausal females\n\nExclusion Criteria:\n\n* Patients unable to switch from prior hypertensive medication.\n* Severe hypertension.\n* Pregnant or nursing females.\n* Patients with Type 1 or Type 2 diabetes mellitus\n* History of immunodeficiency diseases, including a positive Human immunodeficiency virus (HIV) (Enzyme-linked immunosorbent assay \\[ELISA\\] and Western blot) test result.\n* A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.\n\nOther protocol-defined inclusion/exclusion criteria are applied", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Beek en Donk", "country": "Netherlands", "geoPoint": {"lat": 51.54158, "lon": 5.62603}}, {"facility": "Novartis Investigative Site", "city": "Bosch", "country": "Netherlands", "geoPoint": {"lat": 51.27, "lon": 5.59167}}, {"facility": "Novartis Investigative Site", "city": "Den Haag", "country": "Netherlands", "geoPoint": {"lat": 52.07667, "lon": 4.29861}}, {"facility": "Novartis Investigative Site", "city": "Hoogwoud", "country": "Netherlands", "geoPoint": {"lat": 52.71583, "lon": 4.93889}}, {"facility": "Novartis Investigative Site", "city": "Lichtenvoorde", "country": "Netherlands", "geoPoint": {"lat": 51.98667, "lon": 6.56667}}, {"facility": "Novartis Investigative Site", "city": "Lieshout", "country": "Netherlands", "geoPoint": {"lat": 51.52083, "lon": 5.59478}}, {"facility": "Novartis Investigative Site", "city": "Poortvliet", "country": "Netherlands", "geoPoint": {"lat": 51.54417, "lon": 4.14306}}, {"facility": "Novartis Investigative Site", "city": "Utrecht", "country": "Netherlands", "geoPoint": {"lat": 52.09083, "lon": 5.12222}}, {"facility": "Novartis Investigative Site", "city": "Wildervank", "country": "Netherlands", "geoPoint": {"lat": 53.08083, "lon": 6.8625}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Aliskiren/Amlodipine + Placebo to Amlodipine", "description": "During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.\n\nThe patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."}, {"id": "FG001", "title": "Amlodipine+ Placebo to Aliskiren/Amlodipine", "description": "During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.\n\nThe patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "17"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren/Amlodipine + Placebo to Amlodipine", "description": "During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.\n\nThe patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."}, {"id": "BG001", "title": "Amlodipine+ Placebo to Aliskiren/Amlodipine", "description": "During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.\n\nThe patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "31"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.4", "spread": "6.21"}, {"groupId": "BG001", "value": "58.0", "spread": "4.49"}, {"groupId": "BG002", "value": "56.8", "spread": "5.40"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "22"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in the Ankle Foot Volume (AFV) as Measured by Displacement Method", "description": "AFV (mL) was measured using the principle of water displacement using a commercially available foot volumeter. The amount of water displaced in milliliters (mL) equals the volume of the foot/ankle. The study was terminated due to the publication of the results of a near identical study by Fogari et al. Hence, for the current study, no analysis was performed.", "populationDescription": "The study was terminated due to the publication of the results of a near identical study by Fogari et al. Hence, for the current study, no analysis was performed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mL", "timeFrame": "Baseline, 4 weeks", "groups": [{"id": "OG000", "title": "Aliskiren/Amlodipine + Placebo to Amlodipine", "description": "During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.\n\nThe patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."}, {"id": "OG001", "title": "Amlodipine+ Placebo to Aliskiren/Amlodipine", "description": "During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.\n\nThe patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Aliskiren/Amlodipine and Placebo to Amlodipine", "description": "During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patient up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.\n\nThe patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day.", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 2, "otherNumAtRisk": 14}, {"id": "EG001", "title": "Amlodipine and Placebo to Aliskiren/Amlodipine", "description": "During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patient up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.\n\nThe patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day.", "seriousNumAffected": 0, "seriousNumAtRisk": 17, "otherNumAffected": 2, "otherNumAtRisk": 17}], "otherEvents": [{"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}]}, {"term": "Otitis externa", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 14}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}]}, {"term": "Joint swelling", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M7657", "name": "Edema", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}